Estimation of treatment effects and model diagnostics with two-way time-varying treatment switching: an application to a head and neck study
暂无分享,去创建一个
Fan Zhang | Ming-Hui Chen | Qingxia Chen | Xiuyu Julie Cong | Ming-Hui Chen | Qingxia Chen | Fan Zhang | X. Cong
[1] Eric B. Laber,et al. A Robust Method for Estimating Optimal Treatment Regimes , 2012, Biometrics.
[2] T. Louis. Finding the Observed Information Matrix When Using the EM Algorithm , 1982 .
[3] Ian R. White,et al. Randomization-based methods for correcting for treatment changes: examples from the Concorde trial. , 1999, Statistics in medicine.
[4] Joseph G. Ibrahim,et al. Missing covariates in generalized linear models when the missing data mechanism is non‐ignorable , 1999 .
[5] J. Robins,et al. Correcting for Noncompliance and Dependent Censoring in an AIDS Clinical Trial with Inverse Probability of Censoring Weighted (IPCW) Log‐Rank Tests , 2000, Biometrics.
[6] Joseph G Ibrahim,et al. Estimating treatment effects with treatment switching via semicompeting risks models: an application to a colorectal cancer study. , 2012, Biometrika.
[7] Donglin Zeng,et al. New Statistical Learning Methods for Estimating Optimal Dynamic Treatment Regimes , 2015, Journal of the American Statistical Association.
[8] Robert D. Gibbons,et al. Estimating the Efficacy of Receiving Treatment in Randomized Clinical Trials with Noncompliance , 2001, Health Services and Outcomes Research Methodology.
[9] Chengqing Wu,et al. A proposed approach for analyzing post-study therapy effect in survival analysis , 2016, Journal of biopharmaceutical statistics.
[10] Donglin Zeng,et al. Maximum likelihood estimation in semiparametric regression models with censored data , 2007, Statistica Sinica.
[11] S. Murphy,et al. Optimal dynamic treatment regimes , 2003 .
[12] Joseph G Ibrahim,et al. Quantifying the average of the time-varying hazard ratio via a class of transformations , 2014, Lifetime Data Analysis.
[13] I. White. Estimating treatment effects in randomized trials with treatment switching , 2006, Statistics in medicine.
[14] Ulrich Keilholz,et al. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. , 2015, The Lancet. Oncology.
[15] J. Whitehead,et al. Estimating a treatment effect in survival studies in which patients switch treatment , 2002, Statistics in medicine.
[16] S. Chow,et al. Statistical inference for cancer trials with treatment switching , 2005, Statistics in medicine.
[17] J. Robins,et al. Correcting for non-compliance in randomized trials using rank preserving structural failure time models , 1991 .
[18] Susan A. Murphy,et al. Introduction to SMART designs for the development of adaptive interventions: with application to weight loss research , 2014, Translational behavioral medicine.
[19] Yu Cheng,et al. Cumulative incidence regression for dynamic treatment regimens. , 2018, Biostatistics.
[20] Min Zhang,et al. Adjusting for observational secondary treatments in estimating the effects of randomized treatments. , 2013, Biostatistics.
[21] Joseph G Ibrahim,et al. Missing data in clinical studies: issues and methods. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] Keith R. Abrams,et al. Adjusting Survival Time Estimates in the Presence of Treatment Switching , 2014 .
[23] Danyu Lin,et al. Goodness-of-Fit Analysis for the Cox Regression Model Based on a Class of Parameter Estimators , 1991 .
[24] Min Zhang,et al. Estimating treatment effects from a randomized clinical trial in the presence of a secondary treatment. , 2012, Biostatistics.